Fate Therapeutics Inc
NASDAQ:FATE
Fate Therapeutics Inc
NASDAQ:FATE
Price:
4.15 USD
1.72%
Market Closed
Updated:
May 14, 2024
Fate Therapeutics Inc
Interest Income Expense
|
Fate Therapeutics Inc
Interest Income Expense Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fate Therapeutics Inc
NASDAQ:FATE
|
Interest Income Expense
$19.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
109%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-19%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$757m
|
CAGR 3-Years
35%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$563.1m
|
CAGR 3-Years
78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Fate Therapeutics Inc's Interest Income Expense?
Interest Income Expense
19.7m
USD
19.7m
USD
Based on the financial report for Dec 31, 2023, Fate Therapeutics Inc's Interest Income Expense amounts to 19.7m USD.
What is Fate Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
109%
109%
Over the last year, the Interest Income Expense growth was -25%.
You don't have any saved screeners yet
